Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma

Advanced Sarcoma Clinical Trial

Official title:
A Pilot Study of Lenvatinib Plus Pembrolizumab in Patients With Advanced Sarcoma

Status Active, not recruiting

Clinical Trial Summary

The purpose of this study is to find out whether combining the study drugs, lenvatinib and pembrolizumab, is a safe and effective treatment for metastatic soft tissue sarcomas that cannot be removed with surgery.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04784247
Study type	Interventional
Source	Memorial Sloan Kettering Cancer Center
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	March 18, 2021
Completion date	March 2025

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05448820` - YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma	Phase 1/Phase 2
Terminated	`NCT03652298` - Effects of a Neuroscience-based Technique on Cancer Patients Announced of a Palliative Disease Progression and Partners	Phase 2
Withdrawn	`NCT05238831` - SMMART Adaptive Clinical Treatment (ACT) Trial	Early Phase 1
Active, not recruiting	`NCT04242238` - Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas	Phase 1
Recruiting	`NCT06087341` - A Phase I Trial of Memory T Cells Expressing an NKG2D Chimeric Antigen Receptor in Children, Adolescents and Young Adults With Advanced Sarcoma	Phase 1
Completed	`NCT00439686` - Study of ZIO-201 in Advanced Sarcoma	Phase 1/Phase 2